Regarding DNA repair, cancers with mutations in BRCA1/2 (Breast Cancer Associated Genes 1 and 2) can be treated with PARP (Poly-ADP-Ribose-Polymerase) inhibitors originally established in Ovarian Cancer (14, 15). This evidence concerns the gene BRCA1 and cancer.